Shanghai Junshi Biosciences (HKG:1877) reported that loss attributable to owners for 2024 narrowed by 44% to 1.28 billion yuan, from the 2.28 billion yuan loss a year earlier, according to a Thursday filing with the Hong Kong bourse.
Loss per share was 1.30 yuan, from 2.32 yuan loss per share a year ago.
Revenue rose 30% to 1.95 billion yuan from 1.50 billion yuan the previous year.
The company's shares were up 6% at the Hong Kong bourse and 2% at the Shanghai bourse in recent trading.